Ethical considerations in the regulation and use of herbal medicines in the European Union

Anthony Raphael Gatt, Patricia Vella Bonanno, Raymond Zammit
{"title":"Ethical considerations in the regulation and use of herbal medicines in the European Union","authors":"Anthony Raphael Gatt, Patricia Vella Bonanno, Raymond Zammit","doi":"10.3389/fmedt.2024.1358956","DOIUrl":null,"url":null,"abstract":"The regulation and use of herbal medicines is a topic of debate due to concerns about their quality, safety, and efficacy. EU Directive 2004/24/EC on Herbal Medicinal Products was a significant step towards establishing a regulatory framework for herbal medicinal products in the EU, and bridging the gap between conventional and herbal medicines. This Directive allows herbal medicinal products to be marketed in the EU through full marketing authorisation, well-established use, and traditional use of herbal medicinal products. The framework relies on the correlation between the therapeutic claims of herbal medicine and the scientific evidence backing them up: the greater the claims made regarding medicinal benefits, the more evidence is required to substantiate its efficacy and safety. This regulatory framework acknowledges and incorporates traditional knowledge when evaluating herbal medicines, showcasing a balanced approach that values cultural traditions while mandating monographs for traditional herbal medicinal products. Excluding herbal medicines completely limits access to affordable treatment, particularly when they serve as the only alternative for some, and protects consumer autonomy. This EU framework could therefore serve as a practical guidance for the use and regulation of herbal medicines, even outside the EU. In conclusion, it is argued that the same moral imagination and courage shown by regulators in the case of herbal medicines could perhaps be used in the regulatory frameworks of other healthcare products.","PeriodicalId":12599,"journal":{"name":"Frontiers in Medical Technology","volume":"49 42","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medical Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fmedt.2024.1358956","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The regulation and use of herbal medicines is a topic of debate due to concerns about their quality, safety, and efficacy. EU Directive 2004/24/EC on Herbal Medicinal Products was a significant step towards establishing a regulatory framework for herbal medicinal products in the EU, and bridging the gap between conventional and herbal medicines. This Directive allows herbal medicinal products to be marketed in the EU through full marketing authorisation, well-established use, and traditional use of herbal medicinal products. The framework relies on the correlation between the therapeutic claims of herbal medicine and the scientific evidence backing them up: the greater the claims made regarding medicinal benefits, the more evidence is required to substantiate its efficacy and safety. This regulatory framework acknowledges and incorporates traditional knowledge when evaluating herbal medicines, showcasing a balanced approach that values cultural traditions while mandating monographs for traditional herbal medicinal products. Excluding herbal medicines completely limits access to affordable treatment, particularly when they serve as the only alternative for some, and protects consumer autonomy. This EU framework could therefore serve as a practical guidance for the use and regulation of herbal medicines, even outside the EU. In conclusion, it is argued that the same moral imagination and courage shown by regulators in the case of herbal medicines could perhaps be used in the regulatory frameworks of other healthcare products.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
欧盟草药监管和使用中的伦理考虑因素
由于人们对草药质量、安全性和疗效的担忧,草药的监管和使用一直是一个争论不休的话题。欧盟关于草药产品的第 2004/24/EC 号指令是在欧盟建立草药产品监管框架、弥合传统药物与草药之间差距方面迈出的重要一步。该指令允许草药产品通过全面营销授权、完善的使用和草药产品的传统使用在欧盟销售。该框架依赖于草药的治疗声明与支持这些声明的科学证据之间的相关性:对药效的声明越多,就越需要更多的证据来证明其有效性和安全性。这一监管框架在评估草药时承认并纳入了传统知识,展示了一种既重视文化传统又规定传统草药产品专论的平衡方法。将草药排除在外会完全限制人们获得负担得起的治疗,尤其是当草药成为某些人的唯一选择时,同时也保护了消费者的自主权。因此,即使在欧盟以外,欧盟的这一框架也可以作为草药使用和监管的实用指南。最后,本文认为,监管者在草药问题上表现出的道德想象力和勇气或许也可用于其他医疗产品的监管框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Case Report: The effect of automated manual lymphatic drainage therapy on lymphatic contractility in 4 distinct cases Detection of natural autoimmunity to ghrelin in diabetes mellitus Ensuring safety and efficacy in combination products: regulatory challenges and best practices Augmented reality-based software (Echo-QR) for guiding the echographic probe toward the acoustic window: a pilot study Ethical considerations in the regulation and use of herbal medicines in the European Union
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1